OraSure Technologies

Develops and commercializes oral-fluid diagnostic tests

OraSure Technologies

Develops and commercializes oral-fluid diagnostic tests

Overview

OraSure Technologies focuses on creating simple, accessible diagnostic tools and sample-collection systems for infectious diseases. Its core products include rapid tests and molecular diagnostics that use oral-fluid specimens, such as the OraQuick at-home HIV test, and collection devices from DNA Genotek. The company builds end-to-end solutions by combining easy-to-use tests with reliable specimen collection, enabling testing at home, in clinics, or in the field. What sets OraSure apart is its long history of FDA-approved oral-fluid diagnostics and a strategy that blends product development with targeted acquisitions (e.g., DNA Genotek, Sherlock Biosciences) to cover collection, processing, and analysis. The goal is to expand access to accurate, rapid testing for infectious diseases, making diagnostics more convenient and broadly available.

Work here?Claim your company

About OraSure Technologies

Simplify's Rating

Why OraSure Technologies is rated

B-

Rated B on Competitive Edge

Rated B on Growth Potential

Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

201-500

Company Stage

IPO

Headquarters

Bethlehem, PA

Founded

1987

Get referred to OraSure Technologies

See people who can refer or advise you

Simplify's take

What believers are saying

June 2026 Colli-Pee Dx clearance opens U.S. at-home STI screening with Roche volume.
July 2026 Ebola 2.0 EUA strengthens OraSure's outbreak-response franchise during Africa flare-ups.
Nairobi partnership on October 29, 2026 expands SickleSCAN distribution across Kenyan primary care.

What critics are saying

IntelliQuick CT/NG lost its 2026 U.S. launch again after July 2026 FDA feedback.
Q2 2026 diagnostics revenue was only $19.4 million, leaving growth too narrow.
If public-health demand weakens, OraSure's low-margin tests and sample-management business stalls fast.

What makes OraSure Technologies unique

OraSure sells decentralized diagnostics through DNA Genotek, Roche, and self-collection workflows.
June 11, 2026 Colli-Pee Dx clearance links home urine collection to Roche cobas systems.
April 16, 2026 Altai agreement added John Bertrand and governance discipline under pressure.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$137.6M

Above

Industry Average

Funded Over

6 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!

Post IPO Equity Funding Comparison Coming Soon

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Parental Leave
Mental Health Support
Training Programs

Stock Price

Growth & Insights and Company News

6 month growth

1 year growth

-5%

2 year growth

-5%

Daily Political

Nov 6th, 2026

OraSure Technologies (OSUR) expected to announce quarterly earnings on Monday.

OraSure Technologies (OSUR) expected to announce quarterly earnings on Monday. OraSure Technologies (NASDAQ:OSUR - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect OraSure Technologies to announce earnings of ($0.18) per share and revenue of $31.00 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET. OraSure Technologies trading up 2.1%. OSUR stock opened at $3.44 on Friday. The firm has a fifty day moving average price of $3.73 and a two-hundred day moving average price of $3.53. OraSure Technologies has a 1-year low of $2.08 and a 1-year high of $4.58. Analyst upgrades and downgrades. OSUR has been the topic of several analyst reports. Craig Hallum upgraded shares of OraSure Technologies to a "strong-buy" rating in a research note on Friday, October 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of OraSure Technologies in a report on Tuesday, September 1st. Zacks Research upgraded shares of OraSure Technologies to a "hold" rating in a research report on Friday, October 2nd. Finally, Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $3.00. OraSure Technologies company profile. OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows. Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products. Further reading. Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

U.S. Securities and Exchange Commission

Sep 19th, 2026

8-K

Date of Report (Date of earliest event reported): December 19, 2024

Yahoo Finance

Aug 6th, 2026

OraSure Q2 revenue climbs 9.7% to $30.6M, FDA clears STI test as firm targets 2027 profitability

OraSure Technologies reported second-quarter revenue of $30.6 million, up 9.7% sequentially and exceeding guidance. Diagnostic-products revenue rose 14.7% whilst sample-management revenue grew 9%, driven by stronger public-health demand, syphilis testing, and Sickle SCAN. The company achieved regulatory milestones including FDA clearance for its Colli-Pee Dx STI urine-collection kit and Emergency Use Authorisation for the OraQuick Ebola 2.0 test. However, it delayed the expected 2026 US launch of its IntelliQuick CT/NG test. Gross margin improved to 43.5%. OraSure ended the quarter debt-free with $161 million in cash. Management forecast third-quarter revenue of $29.5 million to $32.5 million and continues targeting operating cash-flow break-even entering 2027.

Associated Press

Jul 21st, 2026

OraSure receives FDA emergency use authorization for second-generation Ebola test

OraSure Technologies has received Emergency Use Authorization from the US Food and Drug Administration for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The test can detect all four Ebola viruses known to cause disease in humans using whole blood or cadaveric oral fluid, with results available in 30 minutes. The second-generation test features increased sensitivity and new chemistry compared to the original version, which received full FDA authorisation in 2019. Development was supported by the Biomedical Advanced Research and Development Authority under a 2022 contract. The authorisation comes as Central Africa faces a serious Ebola outbreak centred in the Democratic Republic of the Congo, which has prompted the World Health Organisation to declare a global public health emergency. OraSure is ramping up production to meet potential demand.

Associated Press

Jun 11th, 2026

OraSure gains FDA clearance for at-home STI test collection kit compatible with Roche systems

OraSure Technologies has received FDA clearance for its Colli-Pee Dx Urine Collection Kit, enabling at-home testing for sexually transmitted infections including chlamydia, gonorrhoea, trichomonas and mycoplasma genitalium. The kit works with Roche's cobas molecular diagnostic systems. The device uses proprietary stabilisation technology to maintain urine sample integrity at ambient temperatures, allowing patients to collect first-void urine samples privately at home. Healthcare providers can prescribe the kit, and laboratories can process specimens using Roche's automated platforms. The clearance expands access for individuals with mobility or geographical constraints and enables population-level screening programmes. OraSure subsidiary DNA Genotek will sell the kit, supporting high-volume molecular STI testing through a validated mail-in workflow.

Recently Posted Jobs